I’m not sure that’s true for neuro. Proving effectiveness over placebo is where it is hard in such a heterogeneous group. Also phase 2 trials will be complicated. What is the dosing regime, duration, interval, dose. It’s an old molecule but new delivery, effectively starting from scratch. It’s true that non controlled data from 5 patients exists but given the differences I think it’s even less valuable now
Ann: PRENUMBRA formulation completed for clinical trial use, page-5
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.53 |
Change
0.290(1.90%) |
Mkt cap ! $777.7M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.55 | $15.03 | $861.9K | 56.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 164 | $15.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.53 | 512 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |